



February 27, 2019

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Kind Attn.: Ms. Khyati Vidwans

Dear Madam,

Re: News item captioned "Delhi HC sets aside govt ban on Lupin's anti-diabetic drug Gluconorm - 30" appearing in Business Standard dated February 23, 2019.

We refer to your email dated February 26, 2019 on the aforesaid matter and give below the sequence of events: -

The Central Government, vide Notification No. 4479(E) dated September 7, 2018, prohibited the manufacture and sale/distribution for human use of the fixed-dose combination (FDC) of Pioglitazone 30 mg + Metformin 500 mg.

The Company challenged the aforesaid Notification for its product Gluconorm P 30 before the Hon. High Court of Delhi, which was essentially a non-material product litigation. The Hon. Delhi High Court vide its Order dated February 22, 2019, set aside the Notification and remanded the matter to the Drugs Technical Advisory Board/Sub-Committee to examine the issue regarding the FDC in accordance with the directions issued by the Hon. Supreme Court in this regard.


The Company had also challenged Notification No. 4471(E) for its products Gluconorm PG 1 Forte and Gluconorm PG 2 Forte. The Hon. Delhi High Court vide its Order dated February, 13, 2019, set aside the said Notification with similar directions.

As the above matters were not material in nature, the same did not warrant disclosure to the Stock Exchanges pursuant to Regulation 30 of the SEBI LODR.

Thanking you,

Yours faithfully,

For **LUPIN LIMITED**


R. V. SATAM
COMPANY SECRETARY



LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.
Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com